Cidara Therapeutics (CDTX) Stock Forecast & Price Target

$13.24

+1.29 (+10.79%)

(As of 07/26/2024 ET)

Cidara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 4 Analyst Ratings

Based on 4 Wall Street analysts who have issued ratings for Cidara Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 3 have given a buy rating, and 1 has given a strong buy rating for CDTX.

Consensus Price Target

$71.25
438.14% Upside

High Forecast	$120.00
Average Forecast	$71.25
Low Forecast	$25.00

According to the 4 analysts' twelve-month price targets for Cidara Therapeutics, the average price target is $71.25. The highest price target for CDTX is $120.00, while the lowest price target for CDTX is $25.00. The average price target represents a forecasted upside of 438.14% from the current price of $13.24.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$71.25	$71.25	$71.25	$110.00
Forecasted Upside	438.14% Upside	336.81% Upside	339.74% Upside	209.86% Upside

Get Cidara Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

Ad Darwin

Top Stock Unveiled!

Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.

Get Your Free Report

CDTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CDTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cidara Therapeutics Stock vs. The Competition

Type	Cidara Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.25	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	446.82% Upside	2,840.05% Upside	9.13% Upside
News Sentiment Rating	Very Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
6/20/2024	Cantor Fitzgerald 3 of 5 stars	Reiterated Rating	Overweight
5/16/2024	Needham & Company LLC 3 of 5 stars	Reiterated Rating	Buy ➝ Buy	$25.00	+96.70%
4/25/2024	WBB Securities 1 of 5 stars	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$40.00	+207.69%
4/8/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00	+468.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:43 PM ET.

CDTX Forecast - Frequently Asked Questions

What is Cidara Therapeutics' forecast for 2024?: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Cidara Therapeutics is $71.25, with a high forecast of $120.00 and a low forecast of $25.00.
Should I buy or sell Cidara Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDTX shares.
Does Cidara Therapeutics's stock price have much upside?: According to analysts, Cidara Therapeutics's stock has a predicted upside of 336.81% based on their 12-month stock forecasts.
What analysts cover Cidara Therapeutics?: Cidara Therapeutics has been rated by research analysts at Cantor Fitzgerald, and Needham & Company LLC in the past 90 days.
Do Wall Street analysts like Cidara Therapeutics more than its competitors?: Analysts like Cidara Therapeutics more than other "medical" companies. The consensus rating for Cidara Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CDTX compares to other companies.